cytarabine has been researched along with Carcinoma, Ductal, Breast in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Murawska, M; Niwińska, A; Rudnicka, H | 1 |
Chen, S; Fu, R; Gu, H; Li, Q; Wang, Y; Wu, H; Yuan, K; Zhang, K; Zhang, L | 1 |
Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z | 1 |
3 other study(ies) available for cytarabine and Carcinoma, Ductal, Breast
Article | Year |
---|---|
Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Administration Routes; Female; Humans; Injections, Spinal; Liposomes; Meningeal Neoplasms; Methotrexate; Middle Aged; Prospective Studies | 2015 |
Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Complement C3a; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proteomics; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles | 2006 |